Background: Sleep deprivation is a universal issue that affects individuals in different ways. While some individuals experience a deficit in performance, others experience resiliency as they maintain high levels of physical and mental activity. Sleep loss is known to cause cognitive dysfunction in areas such as learning and memory, but little is known about neural mechanisms that contribute to resilience to this adverse effect. Methods: An existing database of a learning paradigm in sleep deprived and non-sleep deprived 16 to 18-month old C57BL/6 mice was used to identify fast learners and slow learners based on an R2 value representing the learning curve of each individual mouse. Results: Results showed that sleep deprived mice had more slow learners compared to fast learners whereas non-sleep-deprived mice showed the opposite. Hippocampal immunohistochemistry and digital imaging analysis showed sleep deprived, fast learners expressed lower levels of monocyte chemoattractant protein-1 and histone deacetylase 2 and higher levels of synaptophysin and brain-derived neurotrophic factor compared to sleep-deprived slow learners. Conclusions: These observations provide evidence to suggest that sleep-deprived mice that performed well in a cognitive assay show less hippocampal mediated learning impairment and provide the rationale for further investigations into neurobiological resilience to sleep deprivation with increasing age. Keywords: Sleep deprivation, resiliency, learning impairment, aging, neuropathology, hippocampus
29 June 2020 in Aging Pathobiology and Therapeutics
Aging is a complex process driven by seven intertwined pillars that functionally decline with increasing chronologic age. These pillars of aging include stem cell function, mitochondrial function, proteostasis, autophagy, nutrient sensing, metabolism, epigenetic control, and adaptation to stress, macromolecular damage and inflammation. All of the pillars appear to be interconnected such that a change in one, impinges upon others. With so many pillars of aging, it makes drug development to target aging processes equally complex. This leads to the notion that multiple pathways or biological processes need to be targeted to effectively prevent, delay or attenuate aging. The concept of drug combinations as a powerful anti-aging platform is intriguing but has yet to be tested systematically. Insulin function, mTOR (mammalian target of rapamycin) signaling and epigenetic regulation are well-established molecular pathways involved in the pathobiology of aging. Existing drugs that target these pathways include acarbose, rapamycin, and phenylbutyrate, respectively. Acarbose and rapamycin, used as single agents, extend the lifespan of mice. Thus, a cocktail of these drugs with different mechanisms of action would be expected to complement one another and robustly enhance a delay of aging and age-related disease not achievable with mono-therapeutic approaches. Studies to test this concept will be helpful in the development of clinical trials to enhance healthy aging.
29 March 2021 in Aging Pathobiology and Therapeutics
Loss of physical performance, as seen in humans by decreased grip strength and overall physical fitness, is generally accepted to be a consequence of aging. Treatments to delay or reduce these changes or increase resilience to them are generally not available. In this preliminary study, 20-month-old male and female C57BL/6 mice were given either a standard mouse diet or a formulated mouse diet containing rapamycin (14 ppm), acarbose (1000 ppm), and phenylbutyrate (1000 ppm), or a diet containing one half dose of each drug, for 3 months. At the end of the study, performance on a rotarod and grip strength test was compared. In general, mice fed the full dose drug cocktail diet performed better on these assays, with significant improvements in rotarod performance in females fed the full dose cocktail and in grip strength in males fed the full dose cocktail, and females fed the low dose cocktail. These observations provide support for the concept that short term treatment with a cocktail of drugs that targets multiple aging pathways can increase resilience to aging, and suggests that this prototype cocktail could be part of a clinical therapeutic strategy for delaying age-related loss of physical performance in people. Keywords: Healthy aging, physical performance, aging processes, anti-aging drug cocktail, rapamycin, acarbose, phenylbutyrate, aging mice